Biotoxtech Co (086040) Fair Value & Analysis
Healthcare · KR · Market cap 37.1B KRW
Fair value as of: Jun 24, 2026
Analysis
Biotoxtech Co (086040) currently trades at 2,100 KRW, while our model-based Fair Value estimate is 1,757 KRW — implying the stock looks roughly 16.3% overvalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and business consulting and vicegerent of nonclinical trial activities. The company's safety evaluation research field includes general toxicity studies, carcinogenicity studies, local toxicity studies, reproductive and developmental studies, genotoxicity studies, immunotoxicity studies, safety pharmacology, ecotoxicology studies, histopathology/clinical pathology, and juvenile animal toxicity studies. Biotoxtech Co., Ltd. was founded in 2000 and is headquartered in Cheongwon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Biotoxtech Co (086040) undervalued?
What is the fair value of 086040?
What is the quality score of 086040?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.